These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8392392)

  • 1. General features of the heparin-binding serpins antithrombin, heparin cofactor II and protein C inhibitor.
    Pratt CW; Church FC
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):479-90. PubMed ID: 8392392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of thrombin with antithrombin, heparin cofactor II, and protein C inhibitor.
    Whinna HC; Church FC
    J Protein Chem; 1993 Dec; 12(6):677-88. PubMed ID: 8136018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins.
    Jeter ML; Ly LV; Fortenberry YM; Whinna HC; White RR; Rusconi CP; Sullenger BA; Church FC
    FEBS Lett; 2004 Jun; 568(1-3):10-4. PubMed ID: 15196911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of dysthrombins Quick I and II by heparin cofactor II and antithrombin.
    Phillips JE; Shirk RA; Whinna HC; Henriksen RA; Church FC
    J Biol Chem; 1993 Feb; 268(5):3321-7. PubMed ID: 8429008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serpin-glycosaminoglycan interactions.
    Rein CM; Desai UR; Church FC
    Methods Enzymol; 2011; 501():105-37. PubMed ID: 22078533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.
    Sheehan JP; Tollefsen DM; Sadler JE
    J Biol Chem; 1994 Dec; 269(52):32747-51. PubMed ID: 7806495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation.
    Chuang YJ; Swanson R; Raja SM; Bock SC; Olson ST
    Biochemistry; 2001 Jun; 40(22):6670-9. PubMed ID: 11380262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II.
    Cooper ST; Rezaie AR; Esmon CT; Church FC
    Thromb Res; 2002 Jul; 107(1-2):67-73. PubMed ID: 12413592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors.
    Olson ST; Richard B; Izaguirre G; Schedin-Weiss S; Gettins PG
    Biochimie; 2010 Nov; 92(11):1587-96. PubMed ID: 20685328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutagenesis of thrombin selectively modulates inhibition by serpins heparin cofactor II and antithrombin III. Interaction with the anion-binding exosite determines heparin cofactor II specificity.
    Sheehan JP; Wu Q; Tollefsen DM; Sadler JE
    J Biol Chem; 1993 Feb; 268(5):3639-45. PubMed ID: 8429040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic function of antithrombin is dependent on its conformational variation: implication for other serpins.
    Azhar A; Singh P; Rashid Q; Naseem A; Khan MS; Jairajpuri MA
    Protein Pept Lett; 2013 Apr; 20(4):403-11. PubMed ID: 23016581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II.
    Becker DL; Fredenburgh JC; Stafford AR; Weitz JI
    J Biol Chem; 1999 Mar; 274(10):6226-33. PubMed ID: 10037709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis.
    Huntington JA
    J Thromb Haemost; 2003 Jul; 1(7):1535-49. PubMed ID: 12871289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of heparin cofactor II anticoagulant activity.
    Bauman SJ; Church FC
    J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological implications of a 3 A structure of dimeric antithrombin.
    Carrell RW; Stein PE; Fermi G; Wardell MR
    Structure; 1994 Apr; 2(4):257-70. PubMed ID: 8087553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the glycosaminoglycan-binding region of lactoferrin.
    Wu HF; Monroe DM; Church FC
    Arch Biochem Biophys; 1995 Feb; 317(1):85-92. PubMed ID: 7872808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of lysine 173 in heparin binding to heparin cofactor II.
    Whinna HC; Blinder MA; Szewczyk M; Tollefsen DM; Church FC
    J Biol Chem; 1991 May; 266(13):8129-35. PubMed ID: 1902471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of protein C inhibitor activity.
    Neese LL; Pratt CW; Church FC
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):737-46. PubMed ID: 7532447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of heparin action.
    Jackson CM
    Baillieres Clin Haematol; 1990 Jul; 3(3):483-504. PubMed ID: 2176902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin binding to protein C inhibitor.
    Pratt CW; Church FC
    J Biol Chem; 1992 May; 267(13):8789-94. PubMed ID: 1315738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.